ID   FU-266
AC   CVCL_J235
SY   FU 266
DR   Wikidata; Q54835231
RX   Patent=US4574116;
RX   PubMed=6316357;
CC   Characteristics: Produces IgE lambda.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Heterozygous for BRAF p.Lys601Asn (c.1803A>T) (from parent cell line).
CC   Sequence variation: Heterozygous for MSH6 p.Gly141Asp (c.422G>A) (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Ala161Thr (c.481G>A) (ClinVar=VCV000161518) (from parent cell line).
CC   Sequence variation: Homozygous for TRAF3 p.Lys550Leufs*3 (c.1648_1649insT) (from parent cell line).
CC   Derived from sampling site: Peripheral blood.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0566 ! U266B1
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 02-07-20; Version: 12
//
RX   Patent=US4574116;
RA   Kaplan H.S., Teng N.N.H., Lam K.S., Calvo-Riera F.;
RT   "Methods and cell lines for immortalization and monoclonal antibody
RT   production by antigen-stimulated B-lymphocytes.";
RL   Patent number US4574116, 04-Mar-1986.
//
RX   PubMed=6316357; DOI=10.1073/pnas.80.23.7308;
RA   Teng N.N.H., Lam K.S., Calvo Riera F., Kaplan H.S.;
RT   "Construction and testing of mouse -- human heteromyelomas for human
RT   monoclonal antibody production.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:7308-7312(1983).
//